HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6
HC Wainwright & Co. analyst Edward White maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $8 to $6.
InflaRx Submits Request For Emergency Use Authorization To US FDA For Vilobelimab For Treatment Of Critically Ill COVID-19 Patients
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients
EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The
InflaRx: Q2 Earnings Insights
InflaRx (NASDAQ:IFRX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
InflaRx reported EPS of $0.01.
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB).
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Crude Oil Drops 1%; General Motors Earnings Miss Views
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Tuesday.
Why Is Ayala Pharmaceuticals Trading Higher By Around 130%? 45 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) jumped 130% to $2.0001 after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
InflaRx’s Stock Gains Following FDA Fast Track Status To Skin Disease Drug
The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).
InflaRx Climbs More Than 40%, Here’s 58 Biggest Movers From Yesterday
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.